New Therapeutic Strategies for Type 2 Diabetes CME

Methodist DeBakey cardiovascular journal

Volumn 14, Issue 4, 2018, Pages 281-288

  Yehya, Ahmad ^a   Sadhu, Archana R ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

cardiovascular disease; DPP 4; GLP 1 RA; heart failure; incretins; myocardial infarction; SGLT2; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

AGONISTS; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TREATMENT OUTCOME;

BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85061962741     PISSN: None     EISSN: 19476108     Source Type: Journal    
DOI: 10.14797/mdcj-14-4-281     Document Type: Review

References (0)